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Abstract: Thalidomide (Thal), a novel agent in the treatment of multiple myeloma, is presumed
to act through a variety of mechanisms. In the present study, we examined the relationship
between fibroblast growth factor receptor 3 (FGFR3) expression and the therapeutic effect of
Thal. The DNA synthesis of KMS-11 clone, which overexpresses FGFR3, was inhibited by
Thal in a dose-dependent manner; whereas U266 cells, which lack FGFR3 expression, failed
to respond to Thal inhibition. To further examine the intertwining of Thal’s therapeutic effects,
wild-type human full-length FGFR3 cDNA was transfected into U266 cells. FGFR3 transfected
U266 clones revealed increased FGFR3 expression, but resulted in decreased DNA synthesis
and increased apoptosis under Thal treatment. Under Thal treatment, the myeloma proliferation-
related protein, vascular endothelial growth factor (VEGF), and interleukin-6 (IL-6) were
decreased in U266 FGFR3 transfectant as well. These results suggest that Thal inhibits myeloma
cell proliferation and may depend on FGFR3 expression status. To further confirm this
observation, we transfected a plasmid constructed anti-FGFR3 ribozyme (Rz52) into KMS-11
cells. In the ribozyme transfectant KMS-11 clone, FGFR3 expression was decreased; whereas
the effects of Thal in cell growth inhibition were abrogated in KMS-11 Rz52 clone. Further
results suggested that Thal inhibition of DNA synthesis, induction of apoptosis, and down-
regulation of VEGF and IL-6 might be dependent on FGFR3-associated signal transduction
of the ERK and STAT3 phosphorylation pathway. Thus, FGFR3 may be a predictive/surrogate
marker for selection of Thal treatment in myeloma.
Keywords: fibroblast growth factor receptor 3, multiple myeloma, thalidomide, vascular
endothelial growth factor
Introduction
Multiple myeloma (MM) is characterized by the clonal proliferation of malignant
plasma cells in the bone marrow (Vacca et al 1994; Hallek et al 1998). Only 5% of
patients achieve a complete response with conventional therapy (Zaidi et al 2001).
The relapse is largely due to development of MM resistance to chemotherapeutic
agents (Attal et al 1992). Remission following autologous bone marrow transplant
(ABMT) can be accomplished in 26%–45% of patients (Bjorkstrand et al 1995; Tricot
et al 1995; Attal et al 1996; Barlogie et al 1997, 1999; Tosi et al 2002). However, the
majority of MM patients will eventually relapse (Anderson et al 1999; Singhal et al
1999; Stevenson and Anderson 1999).
Vascular endothelial growth factor (VEGF) is a key mediator of tumor
angiogenesis and plays a role in the pathogenesis of hematological malignancies,
including MM (Folkman 1995; Bellany et al 1999; Dankbar et al 2000; Podar et al
2001; Tartaglia et al 2001). VEGF and its receptors Flt-1 (VEGFR-1) and KDR
(VEGFR-2) can be detected in the bone marrow microenvironment (DeVries et 1992;
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Podar et al 2001). VEGF directly induces proliferation and
triggers trans-filter migration of human MM cells expressing
Flt-1, suggesting an autocrine VEGF loop in MM (Bellamy
et al 1999). VEGF can increase expression of several
hematopoietic growth factors in endothelial cells, including
interleukin-6 (IL-6) (Terman et al 1992), which plays a
critical role in the onset of plasma cell tumors in vivo and in
vitro and has an antiapoptotic effect on myeloma cells
(Kawano et al 1988; Suematsu et al 1992; Hilbert et al 1995).
The fibroblast growth factor receptor 3 (FGFR3), the
high affinity receptor for bFGF, was recognized on the
surface of myeloma cells with t(4; 14) translocation (Chesi
et al 1998, 2001). The t(4; 14) (p16.3; q32) chromosomal
translocation occurs in approximately 20% of MM and leads
to the apparent upregulation of FGFR3 (Bergsagel and
Kuehl 2001; De Bont et al 2001). The FGFR3 gene is a
member of the family of the tyrosine kinase receptor, which
binds to a number of related mitogenic fibroblast growth
factors resulting in the activation of complex signaling
pathways and activation of cell proliferation regulation and
cell transformation (Kanai et al 1997). FGFR3 signaling
can substitute for IL-6 in directing growth and survival in a
myeloma cell line, and inhibition of these signals results in
apoptosis (Plowright et al 2000). In our previous report, we
demonstrated that ribozyme-induced FGFR3 down-
regulation inhibited DNA synthesis in addition to VEGF
down-regulation in KMS-11 cells (Qian et al 2005). This
finding suggests that FGFR3 might play a role in the
pathogenesis of MM associated with the t(4; 14) trans-
location, and is a potential therapeutic target for the treatment
of MM.
Thal is a glutamic acid derivative that exerts potent
antiangiogenic activity in experimental systems and in
advanced MM (Singhal et al 1999; Barlogie et al 2001).
Although Thal was initially used to treat MM because of its
known antiangiogenic effects (D’Amato et al 1994), the
mechanism of its activity appears to be more complex and
remains unclear. Recent studies suggested that Thal could
inhibit MM cell growth in vitro directly (Hideshima et al
2000). Furthermore, Thal has shown a broad spectrum of
different effects including inhibiting the production of
cytokines, such as IL-6, VEGF, and bFGF in the bone
marrow (Gupta et al 2001), and studies propose it may also
increase apoptosis (Davies et al 2001). Recent reports of
increased angiogenesis in the marrow of multiple myeloma
patients (Ribatti et al 1999; Vacca et al 1999) further
provided the rationale for its use in treating MM (Singhal et
al 1999; D’Amato et al 2000). The plasma levels of bFGF
in patients with progressive MM were high and decreased
with subsequent response to Thal therapy but remained
controversial in many ways (Kenyon et al 1997; Hideshima
et al 2000; Neben et al 2001). The overall mechanism of
the Thal effect is not completely understood. In this study,
we have begun to characterize the mechanisms of Thal
against human MM cells. We demonstrated that Thal-
induced cytotoxicity in MM cells is associated with FGFR3
status.
Materials and methods
Cell culture
KMS-11, the human myeloma cell line containing the t(4;
14) translocation and overexpression of FGFR3, was kindly
provided by Dr Bergsagel. U266, the human myeloma cell
line that lacks FGFR3, was obtained from the American
Tissue Culture Collection (ATCC). Cells were cultured in
RPMI 1640 medium supplemented with 10% fetal bovine
serum (FBS) and 1% (v/v) penicillin and streptomycin
(100 mg/mL), and were maintained at 37 °C in 5% CO2
atmosphere.
Compound
Thal was purchased from Sigma and dissolved in DMSO
and stored at –20 °C as stock. Drugs were diluted in cultured
medium (10
–2–10
4 µmol/L) with < 0.1% DMSO immediately
before use.
Plasmid construction
To construct the FGFR3 expression vector, a HindIII/Kpn1
fragment was released from the vector containing full-length
human FGFR3 cDNA (a gift from Dr Podolsky’s lab) and
subsequently ligated into HindIII/Kpn1 digested pcDNA3.1
plasmid (Invitrogen, San Diego, CA, USA). Anti-FGFR3
ribozyme expression vector, PTV5Rz52, was designed as
previously reported (Qian et al 2005).
Transfection
Prior to electroporation, cells were washed twice with serum
free RPMI 1640 and resuspended into electroporation buffer
(Eppendorf, Germany) at a concentration of 1.4 × 10
6 viable
cells/mL. The cell suspension was mixed with 20 mg/mL
plasmid in a 2-mm gap electroporation cuvette (Eppendorf,
Germany). The cells were electroporated at a fixed 300 V
and the time constant was 50 ms using a multiporator
(Eppendorf, Germany). The electroporated cells were left
in the cuvette for 10 min at room temperature and transferredTherapeutics and Clinical Risk Management 2005:1(3) 233
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to 60-mm petri dishes containing warm (37 °C), complete
medium and incubated at 37 °C, 5% CO2. The growth
medium was replaced 24 hours after electroporation.
[3H]-thymidine incorporation
assay
DNA synthesis was determined by measuring the
incorporation of radiolabeled thymidine into the nucleic acid
of cells. 2 × 10
4 cells were incubated with 0.5 µCi/mL [
3H]
thymidine for 8 hours at 37 ºC and then washed with ice-
cold phosphate-buffered saline (PBS). The sample was
counted by using the Beckman LS 5000CE Scintillation
Counter. All experiments were performed in triplicate.
Apoptosis and flow cytometry analysis
1 × 10
6 MM cells, cultured 48 hours after treatment with
Thal were harvested, washed with PBS, fixed with 70%
ethanol, and pretreated with 10 mg/mL of RNase (Sigma).
Cells were stained with propidium iodide (PI; 10 mg/mL,
Sigma), and analyzed by flow cytometry. The cell cycle
profile was determined by using the program M software
on an Epics flow cytometer (City of Hope, Core Facility,
CA, USA). Apoptosis was assessed by determining the
percent of cells staining with hypodiploid DNA (sub-G1)
contents. The FTIC labeled Annexin V was stained on the
cells treated or without treatment with Thal for apoptosis
evaluation.
RNA purification and reverse
transcriptase polymerase chain reaction
assay
Total RNA was prepared with RNeasy Mini kits (Qiagen,
CA, USA) according to the manufacturer’s instructions.
Complementary DNA (cDNA) was synthesized by using
SuperScript
™ One-Step Reverse Transcriptase Polymerase
Chain Reaction (RT-PCR) system with platinum Taq
(Invitrogen, Life Technologies). For amplification of FGFR3
cDNA, the sequences of the primers are 5´-TCC CAT GGG
GCC CAC TGC CTG-3´ (FGFR35 sense) and 5´-GCT CGG
GCC GTG TCC AGT AAG-3 (FGFR33C antisense). FGFR3
cDNA was amplified for 35 cycles consisting of denaturing
at 94 °C for 30 s, annealing at 53 °C for 45 s and extending
at 72 °C for 1 min. VEGF primers corresponding to the 3´
and 5´ untranslated regions, 5´-TCG GGC CTC CGA AAC
CAT GA-3´ (sense) and 5´-CCT GGT GAG AGA TCT GGT
TC-3´ (antisense), were used to amplify the known splice
variants, producing products of 516 base pairs (bp) of
VEGF121; 588 bp of VEGF145; 648 bp of VEGF165; 720
bp of VEGF189; and 771 bp of VEGF206. Samples were
amplified for 35 cycles at 94 °C for 30 s, 55 °C for 30 s, and
72 °C for 60 s. VEGF receptor primers were used to amplify
Fms-like tyrosine kinase-1 (Flt-1) 5´-CAA GTG GCC AGA
GGC ATG GAG TT-3´ (sense), 5´-GAT GTA GTC TTT ACC
ATCCTG TTG-3´ (antisense), and the kinase insert domain-
containing receptor (KDR) 5´-CAA CAA AGT CGG GAG
AGG AG-3´ (sense) and 5´-ATG ACG ATG GAC AAG TAG
CC-3´ (antisense). Samples were amplified for 35 cycles at
94 °C for 1 min, 60 °C for 2 min, and 72 °C for 3 min. IL-6
was amplified using the primers 5´-GCG CCT TCG GTC
CAG TTG-3´ (sense) and 5´-CTC CTT TCT CAG GGC
TGA G-3´ (antisense). Samples were amplified for 38 cycles
consisting of 94 ºC for 1 min, 55 ºC for 1 min, and 72 ºC for
3 min. For all PCR reactions we used 25 picomoles of each
primer. The integrity of mRNA in each sample was
confirmed by amplification of β-actin. Polymerase chain
reaction (PCR) products were separated on a 1.2% agarose
gel, stained with ethidium bromide, and photographed. The
intensity of each band was quantified using ImageQuant
software (Molecular Dynamics, Sunnyvale, CA, USA),
based on the area under each peak. Signal intensities of the
VEGF, VEGFR, and IL-6 PCR products were measured and
normalized by the signal intensity of the β-actin PCR
product.
Antibodies and Western blot
analysis
Cells were lysed using lysis buffer: 0.65 mL of ice-cold RIPA
buffer (1 × PBS, 1% Nonidet P-40, 0.5% sodium
deoxycholate, and 0.1% sodium dodecyl sulfate [SDS]) with
freshly added inhibitors: 100 µg/mL phenylmethyl-sulfonyl
fluoride (PMSF), 1 mmol/L sodium orthovanadate, and
30 µL/mL aprotinin. For detection of VEGF and FGFR3
protein, cell lysates were subjected to 7.5% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
transferred to polyvinylidene difluoride (PVDF) membrane.
All antibodies used in this study were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA) and immuno-
blotted with anti-VEGF antibody. The membrane was striped
and reprobed with anti-alpha tubulin Ab to ensure equivalent
protein loading.
To characterize growth signaling, immunoblotting was
also done with antiphospho-specific STAT3 (Tyr705)-R,
anti-STAT3 (F-2), antiphospho-specific ERK (E-4), and anti-
ERK1 (C-16) (Santa Cruz, CA, USA). The membrane was
stripped and reprobed with anti-alpha tubulin Ab to ensureTherapeutics and Clinical Risk Management 2005:1(3) 234
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equivalent protein loading. Immunoblotting was performed
by incubation with the corresponding antibody (1:200
dilution, 1 hour at room temperature) followed by incubation
with alkaline phosphatase conjugated goat anti-mouse
(1:5000 dilution, 1 hour at room temperature), or bovine
anti-goat (1:2000 dilution, 1 hour at room temperature)
secondary antibodies. Immunoreactive bands were
visualized by enhanced chemiluminescence.
Statistical analysis
All experiments were repeated at least three times and each
sample in triplicate in each experiment. The values reported
the mean of triplicate (± SD).
Results
FGFR3 deficient U266 cells resistant to
Thal in contrast to FGFR3
overexpression KMS-11 cells, which are
sensitive to Thal treatment
The effect of Thal on DNA synthesis in MM cells KMS-11
and U266 was determined by measuring 3H-TdR uptake
treated with or without various concentrations of Thal from
10
–2 to 104 µmol/L. DNA synthesis was inhibited in a dose-
dependent manner by Thal in FGFR3 overexpressing KMS-
11 cells and shown in Figure 1a. The DNA synthesis was
inhibited starting from 1 µmol/L of Thal. Fifty-percent
inhibition of DNA synthesis of KMS-11 cells was noted at
100 µmol/L Thal. Under 103 µmol/L of Thal treatment, DNA
synthesis of MS-11 was nearly completely blocked.
However, U266 cells, which lack FGFR3, only a slight
inhibition of DNA synthesis was observed even in a high
concentration of 103 µmol/L Thal and continued to have
resistance to 10
4 µmol/L. The FGFR3 expression was
decreased on the KMS-11 clone in a dose-dependent
manner. Whereas, U266 had no change in its low expression
level (Figure 1b).
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Figure 1 Effect of Thal on DNA synthesis of MM cell lines. 2 × 10
4 cells of
KMS-11 or U266 clone were cultured with concentrations ranging from 10
–2 to
10
4 µmol/L of Thal for 48 hours. 3H-TdR (cpm) uptake were measured as
described in the Materials and Methods section. Values represent the mean
(± SD) of triplicate. The experiments were repeated at least three times. The
FGFR3 protein expression was examined under Thal treatment and
demonstrated on the lower panel (Figure 1b).
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Figure 2 Effect of Thal on DNA synthesis in U266 FGFR3 transfectant clone.
(a) Expression of FGFR3 in transient transfection U266 clone. U266 cells were
transfected with the indicated plasmids as described in the Materials and Methods
section. RT-PCR assay shows the expression of FGFR3 in FGFR3 transfected
U266 clones. (b) The transfectants were cultured with concentrations ranging
from 10–2 to 10
4 µmol/L of Thal. U266 parental cells demonstrated similar
results as the U266 vector transfectant. The results demonstrated here are only
from U266 vector transfectant clone. 3H-TdR (cpm) uptake was measured as
described in the Materials and Methods section. Values represent the mean
(± SD) of triplicate cultures. The experiments were performed in triplicate.Therapeutics and Clinical Risk Management 2005:1(3) 235
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The Thal resistant phenotype of U266
can be circumvented by transfecting
FGFR3 into U266 cells
To further confirm the effect of Thal inhibition of MM cell
growth as associated with FGFR3, the full-length human
FGFR3 cDNA was transfected into U266 cells. The
expression of FGFR3 was examined by RT-PCR to confirm
the successful transfection (Figure 2a). DNA synthesis was
then determined by measuring 
3H-TdR uptake for FGFR3
transfected U266 clone cultured from 10
–2 to 10
4 µmol/L
Thal for 48 hours. The FGFR3 transfected U266 clone
revealed increased thymidine incorporation compared with
U266 and vector transfectant in low dose Thal (< 10 µmol/L).
However, DNA synthesis was inhibited in a dose-dependent
manner from 10 to 10
4 µmol/L concentration by Thal
(Figure 2b). Fifty-percent inhibition of DNA synthesis was
noted at 100 µmol/L Thal. In contrast, there is no significant
change in 
3H-TdR incorporation that could be observed at
100 µmol/L Thal in U266 and vector transfectant. These
results further confirm that inducing FGFR3 expression can
circumvent U266 resistance to Thal.
Thal-induced apoptosis can be
enhanced in FGFR3 transfected U266
clone
To further analyze the mechanism of Thal-induced inhibition
of DNA synthesis, flow cytometry was employed to examine
KMS-11, parental U266 cells, U266 vector transfectant
clones, and U266 FGFR3 transfectant clones. These cells
were treated with and without 1 µmol/L, 10 µmol/L, or
B.
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Figure 3 Effect of Thal on the apoptosis and cell cycle profile of flow cytometry analysis in MM cells. KMS-11, U266 parental cells, and U266 FGFR3 transfectant
clones were cultured with 1 µmol/L, 10 µmol/L, and 100 µmol/L Thal for 72 hours. Cultures in media control alone served as a negative control. (a) Cells were then
stained with PI, and cell cycle profile was determined by flow cytometric analysis. (b) The histogram showing the relative ratio of Thal of Sub-G1 cells treated to
untreated of each clone. (c) Annexin staining confirmed the apoptosis related with Thal treatment.
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100 µmol/L Thal for 48 hours. As shown in Figure 3a, Thal
increased the sub-G1 population of KMS-11 cells; in
addition there was a dose-dependent increase in apoptosis
(from 10 to 100 µmol/L). In contrast, in parental U266 cells
as well as U266 vector transfectant (data only show U266
parental clone), Thal only induced G1 growth arrest but did
not increase sub-G1 population. This finding confirms that
parental U266 cells are resistant to Thal-induced apoptosis.
Of interest, U266 FGFR3 transfectant clone also
demonstrated increased sub-G1 population in a dose-
dependent manner by Thal. In comparing sub-G1 population
from KMS-11 to U266 FGFR3 transfectants there was a
similar level of apoptosis after Thal treatment. The relative
ratio of sub-G1 population after Thal treated to untreated
were further summarized in Figure 3b, which suggested
FGFR3 could circumvent the Thal resistant phenotype of
U266 cells at higher doses of Thal. The FTIC labeled
Annexin V stained the cell and confirmed the enhanced
apoptosis associated with Thal-induced cell growth
inhibition in U266 transfected FGFR3 clones (Figure 3c).
Effect of Thal dependence on VEGF,
VEGF receptor, and IL-6 expression in
U266 FGFR3 transfectant clone
Thal dependent on FGFR3 status may regulate downstream
expression of VEGF and corresponding receptors associated
with MM cells. U266 parental and FGFR3 transfectant
clones were cultured with 1 µmol/L, 10 µmol/L, or 100 µmol/L
Thal for 48 hours to determine the effect of Thal dependency.
VEGF expression was determined by RT-PCR, as shown in
Figure 4a. VEGF mRNA expression was similar in the
treated and untreated U266 cells (Figure 4a, left panel). The
U266 FGFR3 transfectant demonstrated higher VEGF
mRNA expression than U266 parental cell in the non-treated
control group (Figure 4a, right panel). However, VEGF
mRNA was inhibited in a dose-dependent manner by Thal
in the U266 FGFR3 transfectant clone. The VEGF mRNA
decreased to 50% of the control in 10 µmol/L Thal and
further decreased in 100 µmol/L Thal treated (Figure 4a,
right panel). VEGF protein levels were detected by Western
bolt, as shown in Figure 4b. In the left panel, parental U266
cells revealed no changes in VEGF protein expression under
Thal treatment. VEGF protein expression was higher in the
U266 FGFR3 transfectant clone than in the parental cell,
but inhibited in a dose-dependent manner by Thal. In the
U266 FGFR3 transfectant clone, decreased VEGF parental
expression started from 10 µmol/L then further decreased
to undetectable levels at 100 µmol/L of Thal (Figure 4b,
right panel). The VEGF receptor Flt-1mRNA was further
examined by RT-PCR and is shown in Figure 4c. Flt-1
mRNA was equally expressed, but was not inhibited by Thal
in both FGFR3 transfected U266 clone and parental U266
cells. IL-6 mRNA expression, which is known to be
associated with FGFR3 expression, was also determined by
RT-PCR and is shown in Figure 4c. Interestingly, the
expression of IL-6 mRNA was slightly increased by high-
dose treatment of Thal in the parental U266 cells, but was
significantly inhibited in a dose-dependent manner by Thal
in FGFR3 transfected U266 clone. The IL-6 mRNA
expression decreased to 30% of the control with 10 µmol/L
Thal and approximately 10% of the control with 100 µmol/L
of Thal in the U266 FGFR3 transfectants. These findings
confirmed our previous observation that FGFR3 expression
is associated with VEGF expression. Furthermore, the
FGFR3 overexpression in U266 clone enhanced Thal
inhibition of VEGF and IL-6 expression.
Ribozyme cleaved overexpressing
FGFR3 mRNA confers KMS-11 cells
resistance to Thal treatment
We previously reported that Rz52 ribozyme could effectively
cleave overexpressing FGFR3 mRNA of KMS-11 cells
(Qian et al 2005). To further examine whether eliminating
FGFR3 expression may desensitize KMS-11 to Thal, the
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Figure 4 Effect of Thal on VEGF, VEGF receptor-1 (Flt-1), and IL-6 expression
in FGFR3 transfected U266 clone. The U266 cells and FGFR3 transfected U266
clone were cultured with 10 µmol/L and 100 µmol/L Thal for 48 hours. Cultures
in media control alone served as a negative control. (a) RT-PCP assay of VEGF
mRNA expression was performed as described in the Materials and Methods
section. (b) Western blot analysis, probed with anti-VEGF, shows the expression
of VEGF in MM cell lines. (c) Expression of IL-6 and Flt-1 mRNA was examined
by RT-PCT as described in the Materials and Methods section. β-actin was probed
as a control for RT-PCR assay and α-tubulin was the control for Western blot.Therapeutics and Clinical Risk Management 2005:1(3) 237
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Rz52 transfected KMS-11 cell designated KMS-11 Rz52
transfectant clone was examined. After treatment with
100 µmol/L Thal, the parental KMS-11 cells demonstrated
a 50% decrease in 
3H thymidine incorporation compared
with control. The KMS-11 Rz52 transfectant clone
demonstrated an 80% decrease in thymidine incorporation
as shown in Figure 5a. In Figure 5b, the DNA synthesis of
Rz52 transfected KMS-11 clone was determined by
measuring 3H-TdR uptake treated with or without 1 µmol/L,
10 µmol/L, or 100 µmol/L Thal for 48 hours and revealed
no further inhibition. This result suggested that Thal
inhibition of DNA synthesis of KMS-11 cells could be
abrogated by anti-FGFR3 ribozyme (Rz52). Thal inhibition
of myeloma cell growth associated with FGFR3 status was
confirmed.
Ribozyme cleaved FGFR3 could further
block Thal induced inhibition of VEGF
and IL-6 expression in KMS-11 cells
We previously reported that VEGF and IL-6 expression in
Rz52 transfected KMS-11 clone decreased to 50% of the
parental KMS-11 cells (Qian et al 2005). To further confirm
that Thal inhibition of VEGF and IL-6 expression was
associated with FGFR3 status, Rz52 transfected KMS-11
clones were treated with or without 1 µmol/L, 10 µmol/L,
or 100 µmol/L Thal for 48 hours before examination. VEGF
expression was determined by RT-PCR, as shown in Figure
6a. VEGF mRNA expression was inhibited by Thal and
decreased to 50% of the control in KMS-11 parental cells;
whereas, Rz52 transfected KMS-11 clone decreased VEGF
mRNA expression as compared with KMS-11 parental cell
in the control group and it remained unchanged under Thal
100 µmol/L treatment. VEGF protein levels were detected
by Western blot and demonstrated consistent findings with
RT-PCR as shown in Figure 6b. Flt-1mRNA was detected
by RT-PCR as shown in Figure 6c. Flt-1 mRNA was
expressed but was not inhibited by Thal in both KMS-11
parental cells and PTV5Rz52 transfected KMS-11 clone.
IL-6 mRNA expression was determined by RT-PCR and
shown in Figure 6c. Expression of IL-6 mRNA was inhibited
in a dose-dependent manner by Thal in KM-11 cells and
decreased to 30% of the control in 100 µmol/L Thal
treatment. IL-6 expression in Rz52 transfected KMS-11
clones was unchanged even at the higher concentration of
100 µmol/L. These findings suggested that Thal decreased
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Figure 5 Effects of Thal on inhibiting DNA synthesis were abrogated by anti-
FGFR3 ribozyme in KMS-11 clone. (a) 3H-TdR uptake was measured in 2 × 10
5
KMS-11 cells. The cells were cultured with concentrations ranging from 1 µmol/L
to 100 µmol/L of Thal for 48 hours and compared with KMS-11 PTV5Rz52
transfectant (Rz52). (b) 2 × 10
5 Rz52 transfected KMS-11 clones were cultured
with 1 µmol/L, 10 µmol/L, and 100 µmol/L of Thal. Cultures in media alone
served as a negative control. 3H-TdR (cpm) uptake was measured 48 hours after
treatment with Thal. Values represent the mean (± SD) of triplicate cultures.
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Figure 6 Effects of Thal on inhibition of VEGF and IL-6 were halted by anti-
FGFR3 ribozyme in KMS-11 cells. The KMS-11 cells were cultured with 10 µmol/L
and 100 µmol/L Thal, and KMS-11 Rz52 transfectant clone were cultured only
with 100 µmol/L Thal for 48 hours. Cultures in media control alone served as a
negative control. (a) RT-PCP assay of VEGF mRNA expression was performed as
described in the Materials and Methods section. (b) Western blot analysis, probed
with anti-VEGF, shows the expression of VEGF in MM cell lines. (c) Expression
of IL-6 and Flt-1 mRNA was examined by RT-PCT as described in the Materials
and Methods section in MM cell lines. β-actin mRNA was used as a control
RT-PCR. Whereas, α-tubulin was used as a control for the Western blot.Therapeutics and Clinical Risk Management 2005:1(3) 238
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FGFR3 associated with VEGF and IL-6 inhibition. The
ribozyme down-regulation of FGFR3 could block Thal
induced down-regulation of VEGF and IL-6 expression in
KMS-11 cell. This observation is consistent with our above
finding.
Phosphorylation of STAT3 and ERK is
responsible for Thal dependent on
FGFR3 status
STAT3 is a key mediator involved in cytokine signaling.
After Thal treatment, Western blot analysis was performed
using a phospho-specific antibody that binds to
phosphorylated STAT3 and total STAT3. As shown in
Figure 7, phosphorylation of STAT3 was inhibited in a dose-
dependent manner by Thal in KMS-11 parental cells.
Ribozyme-cleaved FGFR3 expression, led to the decreased
expression of phosphorylated STAT3. Phosphorylated
STAT3 has lower expression in KMS-11 Rz52 transfectant
clone than in parental KMS-11 cells (Figure 7, top panel).
The expression of phosphorylated STAT3 in U266 parental
cells revealed extremely low levels with no change after
Thal treatment. Whereas in U266 FGFR3 transfectant clone,
the same expression level of phosphorylated STAT3 was
the same in the KMS-11 cells. Thal inhibits phosphorylated
STAT3 in U266 FGFR3 transfectant clone in the same
manner as KMS-11 cells. Total STAT3 was expressed in all
the above clone and was not inhibited by Thal in any dose
range.
Since cytokines, such as VEGF and IL-6, are not only
activated by the JAK-STAT signaling pathway, but also
regulate members of MAPK family, we then examined
phosphorylation of ERK and ERK1 after Thal treatment.
Phosphorylated ERK was inhibited by Thal in a dose-
dependent manner in both parental KMS-11 cells and U266
FGFR3 transfectant clones, but the KMS-11 Rz52
transfectant clone and parental U266 cells revealed no
change in phosphorylated ERK after Thal treatment. ERK1
expression was unchanged in all cell lines after Thal
treatment. These results confirmed that the therapeutic effect
of Thal dependent on FGFR3 status, may send transduction
signals through phosphorylation of STAT3 and ERK.
Western blot analysis with anti-tubulin antibody confirmed
the equivalent protein loading.
Discussion
Our results demonstrate that the anti-MM effect exerted by
Thal is associated with FGFR3 status. The t(4; 14)
translocation occurs in 20% of multiple myeloma and results
in ectopic expression of FGFR3 (Bergsagel and Kuehl 2001;
De Bont et al 2001). Ectopic expression of FGFR3 promotes
myeloma cell proliferation and prevents apoptosis (Kanai
et al 1997). The effect of Thal in MM has been investigated
both in vivo and in vitro settings. At high concentrations
Figure 7 Effect of Thal on phosphorylation of STAT3, ERK, and ERK1 protein. Cells were cultured with 1 µmol/L, 10 µmol/L, and 100 µmol/L Thal for 48 hours and
then were harvested. Whole cell lysates (40 ng) were analyzed by Western blot with specific antiserum against (from the top): STAT-phosphorylated (STAT-P), STAT3,
ERK-phosphorylated (ERK-P), and ERK1. Western blot analysis for α-tubulin confirmed equal protein loading as a control. Detailed methodology is described in the
Materials and Methods section.Therapeutics and Clinical Risk Management 2005:1(3) 239
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(100 µmol/L), DNA synthesis is inhibited in MM cells in
vitro (Hideshima et al 2000). In our study, FGFR3
overexpressing KMS-11 cells were exposed to Thal, with
the observation that it inhibited DNA synthesis and induced
apoptosis in a dose-dependent fashion. Our findings further
suggested that the therapeutic effects of Thal-induced
apoptosis might be associated with FGFR3 status resulting
in down-regulation of VEGF and IL-6. The lack of FGFR3
expression in U266 cells demonstrated resistance to Thal.
This was confirmed in a previous finding (Sampaio et al
1991). To investigate whether the Thal therapeutic effect is
associated with FGFR3 status, the wild-type human FGFR3
cDNA was transfected into U266 cells in addition to the
ribozyme cleaved FGFR3 in KMS-11 cells. Our results
suggested that Thal inhibition of MM cell proliferation may
be dependent with FGFR3 expression status in vitro.
IMiDs, and to a lesser extent Thal, induced apoptosis of
the myeloma MM.IS clone, which is consistent with our
current finding (Hideshima et al 2000). Both MM.IS and
KMS-11 cells treated with Thal increased sub-G1 cells on
flow cytometry in vitro. However, it has been demonstrated
that the MM.IS clone lacks FGFR3 expression. Therefore,
whether the MM.IS clone response to Thal may be secondary
to a non-FGFR3-derived mechanism requires further
exploration. Moreover, the dexamethasone resistant clone,
myeloma Hs Sultan cells, demonstrated resistance to Thal
as well. The Hs Sultan clone is also known to possess low
FGFR3 expression that is similar to the U266 clone. Both
of these clones are resistant to Thal treatment, suggesting
that low FGFR3 might play a role in Thal resistance, at least
in part. P53 may also play an important role in Thal
sensitivity. The P53 mutant status may also confer resistance
to Thal. The cells that possess wild-type P53 may down-
regulate p21, thereby facilitating G1 to S transition and
enhance susceptibility to apoptosis (Hideshima et al 2000).
Whether, FGFR3 expression related Thal efficacy was
independent from p53 requires further elucidation.
It has been known that the inhibiting effects of Thal in
MM are associated with the down-regulation and decreased
secretion of cytokines: tumor necrosis factor (TNF)-α
(Sampaio et al 1991), IL-6, and VEGF (D’Amato et al 1994).
In MM patients, VEGF is expressed and secreted by tumor
cells as well as bone marrow stromal cells (Bellamy et al
1999; Dankbar et al 2000). This may account for, at least in
part, the increased micro vessel density observed in the bone
marrow of patients with MM and correlates with disease
progression and poor prognosis (Vacca et al 1994, 1999).
Clinical responses to Thal were observed in MM patients
who were refractory to conventional and high-dose therapy
(Ribatti et al 1999). In addition to inhibition of VEGF-
induced angiogenesis in bone marrow, Thal may also block
VEGF-induced direct effects on cell growth and proliferation
of MM (D’Amato et al 1994). Recent clinical studies
suggested that there is a correlation with Thal treatment and
decreased VEGF levels in clinical responders. Whereas, in
nonresponders, the VEGF level in plasma remain steady
after Thal treatment (Tosi et al 2002). Our results apparently
support this observation that Thal suppresses VEGF
expression dependent on FGFR3 status. However, whether
FGFR3 expression may play an important role in
determining the response of Thal treatment requires further
investigation. Of interest, IL-6 is also associated with the
growth regulation of human MM (Anderson et al 1989;
Hallek et al 1998). It has been shown that FGFR3
overexpressing in the B9 clone exhibits enhanced
proliferation in the presence of IL-6. Furthermore, this
transfectant exhibits IL-6 independent cell growth
(Plowright et al 2000). In some studies, exogenous IL-6
demonstrated resistance to Thal, as well as the IMiDs on
some MM clone, suggesting that these novel drugs may, at
least in part, function by inhibiting IL-6 production
(Hideshima et al 2000). In our studies, expression of IL-6
was inhibited by Thal in KMS-11 cells, coupled with
inhibition of cell growth, further suggesting that IL-6 is
involved in Thal-induced MM inhibition. In the U266
FGFR3 transfectant clone, Thal inhibited IL-6 expression
(see Figure 4). These findings suggested that IL-6 inhibition
is also dependent on FGFR3 status. This result may suggest
FGFR3 complement IL-6 in certain MM cells. However,
the IL-6 expression increased in parental cells under high
dose Thal treatment suggested a more complicated
regulation involving IL-6. Thus, the different effects seen
with Thal treatment in MM patients and the various MM
cell lines may be explained by the expression of FGFR3.
Interestingly, bFGF (the ligand of FGFR3) was also
noticed to be a prognostic factor in MM patients after Thal
treatment (Kenyon et al 1997; Neben et al 2001). It has been
reported that bFGF levels in MM patients decreased and is
associated with response to Thal treatment (Kenyon et al
1997). In recent studies however, no decline in bFGF levels
after a 6-month follow-up was found in Thal treated patients
(Neben et al 2001). However, adding bFGF into the medium
of MM cells increased MM cell proliferation, suggesting
that bFGF might lead to progression of MM cells. Moreover,
the effect of bFGF in MM cells is FGFR3 dependent. It has
been reported that overexpression of mutant FGFR3 led toTherapeutics and Clinical Risk Management 2005:1(3) 240
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bFGF independent growth in L6 clones, whereas wild-type
FGFR3 is bFGF dependent (Plowright et al 2000). Thus,
the functional role of bFGF is dependent on FGFR3 status.
Most likely, an effect of Thal on cell surface receptors or
intracellular signaling events rather than bFGF level could
explain its efficacy in patients.
STAT3 has been classified as an oncogene because the
constitutively active STAT3 can mediate oncogenic
transformation in MM cells and tumor transformation in
mice (Bromberg et al 1999; Catlett-Falcone et al 1999;
Funamoto et al 2000). Constitutive activation of STAT3
signaling can confer resistance to apoptosis in human
myeloma cells 46 and can also up-regulate the expression
of VEGF and promote tumor angiogenesis through the up-
regulation of VEGF (Funamoto et al 2000). Overexpression
of FGFR3 or mutant FGFR3 displayed increased
phosphorylation of STAT3. In our study, the Western blot
of ERK1, STAT3, and their phosphorylation were examined.
The phosphorylation of ERK and STAT3 was decreased in
a dose-dependent manner after Thal treatment in parental
KMS-11 cells and the FGFR3 transfected U266 clones, but
not in parental U266 cells. These findings suggest that the
FGFR3 mediated Thal effect occurs via phosphorylation of
ERK and STAT3 in MM cells. Other studies have
demonstrated that VEGF and IL-6-induced proliferation of
MM cells is mediated through the MAPK cascade. Using
either MAPK antisense oligonucleotide or the MEK1
inhibitor PD98059 can abrogate MAPK signal transduction,
which confirmed this hypothesis (Ogata, Chauhan, Teoh, et
al 1997; Ogata, Chauhan, Urashima, et al 1997; Hideshima
et al 2000). In our prior experiments, ribozyme-induced
down-regulation of FGFR3 inhibited proliferation of KMS-
11 cells and inhibited phosphorylation of ERK and STAT3.
Ribozyme-induced FGFR3 down-regulation in KMS-11
cells negated the effects of Thal on the phosphorylation
status of ERK and STAT3. These results suggest that Thal
inhibition of DNA synthesis, induction of apoptosis, and
down-regulation of VEGF may be mediated via a FGFR3-
associated signal transduction of the ERK and STAT3
phosphorylation pathway. These studies support the
hypothesis that Thal inhibition of MM is, at least in part,
dependent on FGFR3 status in myeloma cells. The limitation
of our observation is that in vitro findings may not directly
imply in vivo or in human therapeutic settings. Since Thal
requires the liver to activate its metabolites, the dose of Thal
in clinical use is different as in vitro investigation. Therefore,
the in vitro finding may not directly correspond to clinical
scenarios. To further confirm our observations, the Xenograft
animal study will be tested next. After confirmation using
this model, FGFR3 may become a predictive/surrogate
marker for selection of Thal treatment in myeloma.
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